Trial Profile
A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of EGFR (Vectibix® Sequence)-Targeted EnGeneIC Dream Vectors Containing Doxorubicin (EGFR(V)-EDV-Dox) in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Doxorubicin (Primary)
- Indications Astrocytoma; Glioblastoma
- Focus Adverse reactions
- Acronyms CerebralEDV
- Sponsors EnGeneIC
- 14 Feb 2019 Planned End Date changed from 1 Dec 2019 to 1 Jun 2020.
- 14 Feb 2019 Planned primary completion date changed from 1 Feb 2019 to 1 Dec 2019.
- 01 Feb 2017 Status changed from not yet recruiting to recruiting